ESC 365 - Is empagliflozin still cardioprotective in SGLT2 KO mice?

ESC Professional Premium Access

Is empagliflozin still cardioprotective in SGLT2 KO mice?

Session: Basic and Translational Late-Breaking Science 1

Topic: Ischaemia, Infarction, Cardioprotection

Speaker: Miss S. Chen (Amsterdam, NL)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Miss Sha Chen

AMC Medical Research BV, Amsterdam (Netherlands (The))

1 presentation

0 follower

3 more presentations in this session

Intravascular administration of soluble Sars-CoV-2 Spike protein triggers non-infective heart and lung inflammation and vascular pericytes rarefaction in healthy mice.

Speaker: Doctor E. Avolio (Bristol, GB)

CRISPR/Cas9 editing of CaMKII as a strategy for cardioprotection against ischemia/reperfusion injury.

Speaker: Professor S. Lebek (Regensburg, DE)

Plasma of COVID-19 positive patients promote oxidative stress and proinflammatory responses in endothelial cells: Potential role of the pro-inflammatory cytokines/SGLT2 pathway.

Speaker: Doctor A. Mroueh (Strasbourg, FR)

Access the full session

Basic and Translational Late-Breaking Science 1

Speakers: Miss S. Chen, Doctor E. Avolio, Professor S. Lebek, Doctor A. Mroueh

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources